(ZNTL) Zentalis Pharmaceuticals, Inc. Business Model Canvas Research

Pfizer, Eli Lilly, and GlaxoSmithKline form a major pharma partner set for Zentalis Pharmaceuticals, Inc.; these ties point to prior or ongoing licensing and collaboration work and help extend Zentalis’ external R&D reach. In 2025, all three kept multibillion-dollar R&D budgets, so they remain credible channels for oncology know-how and deal flow.

• 3 large pharma partners
• Signals licensing history
• Supports outside R&D access

Zentera Therapeutics (Cayman), Ltd. is a collaboration partner in Zentalis Pharmaceuticals, Inc.’s oncology development model, helping share R&D risk and keep programs moving. This kind of partner network supports shared innovation and widens Zentalis Pharmaceuticals, Inc.’s asset base across cancer targets.

• Supports program progression
• Shares development risk
• Broadens oncology partnerships

ZN-d5 is in Phase 1 for non-Hodgkin’s lymphoma and acute myelogenous leukemia, while ZN-e4 is in Phase 1/2 for advanced non-small cell lung cancer. These two programs widen Zentalis Pharmaceuticals, Inc.’s pipeline across hematologic and solid tumors, with early-stage readouts driving the next value inflection points.

• ZN-d5: Phase 1, blood cancers
• ZN-e4: Phase 1/2, lung cancer
• Pipeline spans two tumor classes

Zentalis Pharmaceuticals, Inc. is designing BCL-xL heterobifunctional degraders that recruit E3 ligases absent in platelets, aiming to spare normal platelet biology and reduce the dose-limiting thrombocytopenia seen with earlier BCL-xL inhibitors. Human platelet counts are typically 150,000 to 450,000 per µL, so this selectivity is central to safer dosing.

• BCL-xL degradation is the core activity
• Uses platelet-sparing E3 ligases
• Targets less thrombocytopenia risk

Zentalis Pharmaceuticals, Inc. uses ongoing clinical trials to build its core data asset: safety, efficacy, and biomarker evidence. ZN-c3 also has a tumor-agnostic predictive biomarker trial, which helps refine patient selection and decide whether to advance or stop programs.

• Safety and efficacy data from active studies
• ZN-c3 tumor-agnostic biomarker trial
• Supports patient selection and go/no-go calls

Zentalis Pharmaceuticals, Inc. is based in New York, New York, and that headquarters is the core hub for corporate, scientific, and partnering work. For a clinical-stage biotech with no product revenue reported in FY2025, the New York base is a key operating asset that supports pipeline decisions, investor relations, and deal making.

• Central office for leadership and R&D coordination
• Supports partnering and business development
• Anchors a clinical-stage, pre-revenue model

ZN-c3’s tumor-agnostic predictive biomarker can sharpen patient selection across cancers, improving the odds of finding responders and limiting wasted treatment. For Zentalis Pharmaceuticals, Inc., that supports a more personalized oncology model and can raise trial efficiency as the company advances precision-based development.

• Better responder enrichment
• Less off-target exposure
• More personalized oncology

Zentalis Pharmaceuticals, Inc.’s BCL-xL degrader design aims to spare platelets by using an E3 ligase route that platelets lack, which directly tackles the class’s main safety risk: thrombocytopenia. That makes it a clear differentiator for safer dosing and wider therapeutic use in oncology.

• Targets BCL-xL while sparing platelets
• Uses an E3 ligase absent in platelets
• Addresses dose-limiting thrombocytopenia
• Supports safer cancer development

Zentalis Pharmaceuticals, Inc. uses scientific and medical dialogue to keep investigators, key opinion leaders, and conference audiences updated on trial progress, which supports credibility in oncology. In FY2024, the Company spent $224.1 million on research and development and ended the year with $317.7 million in cash, cash equivalents, and investments, showing why clear clinical updates matter.

• Updates investigators and KOLs
• Shares trial data at conferences
• Builds oncology credibility

As a clinical-stage biotech, Zentalis Pharmaceuticals, Inc. keeps investors updated on trial readouts, pipeline moves, and funding needs because access to capital depends on trust. In its latest filings, the Company had roughly $270 million in cash and investments, so every update matters for runway and dilution risk.

• Shares trial milestones.
• Explains financing needs.
• Supports capital access.

Zentalis Pharmaceuticals, Inc. uses oncology meetings and journal papers to share clinical and preclinical data, which reaches physicians, researchers, and deal partners. This channel helps validate the pipeline in public and can support earlier partnering talks.

• Shares trial data at oncology conferences
• Publishes papers for scientific review
• Builds trust with experts and partners
• Supports pipeline validation

Zentalis Pharmaceuticals, Inc. uses SEC filings, press releases, and investor presentations to share pipeline progress and business updates. These channels are key for capital-markets visibility, especially as the Company reports clinical milestones, cash use, and financing needs to investors.

• SEC filings: formal disclosure
• Press releases: pipeline updates
• Investor materials: strategy clarity

Zentalis Pharmaceuticals, Inc. targets advanced non-small cell lung cancer, which makes up about 85% of lung cancer cases, plus biomarker-defined patients who fit precision oncology profiles. ZN-e4 is being tested in advanced NSCLC, and ZN-c3 includes a tumor-agnostic biomarker study, so the segment is driven by molecular selection, not broad-use treatment.

• Advanced NSCLC: about 85% of lung cancer.
• ZN-e4: advanced NSCLC focus.
• ZN-c3: tumor-agnostic biomarker study.

Zentalis Pharmaceuticals, Inc. targets hematologic oncology patients through ZN-d5, which is being developed for non-Hodgkin’s lymphoma and acute myelogenous leukemia. It also sells access to its science through pharmaceutical and licensing collaborations, so partner organizations are a core customer segment, not just a side channel.

• ZN-d5 addresses lymphoma and AML
• Partners support licensing and collaboration revenue
• Biopharma partners shape go-to-market reach

Zentalis Pharmaceuticals, Inc. carries corporate, finance, legal, HR, audit, and SEC reporting costs to run a public company, and those overheads support its New York operating base. These general and administrative expenses are part of SG&A and rose as compliance, payroll, and office support stayed in place.

• Corporate, finance, legal, HR support
• Public-company compliance adds cost
• Funds New York operating structure

Zentalis Pharmaceuticals, Inc. relies on external IP and partner deals for some programs, so this cost line can include upfront fees, development milestones, and sales royalties. In licensed biotech portfolios, these obligations usually rise when a program advances, so the burden is variable rather than fixed.

• Upfront fees
• Milestone payments
• Royalty costs
• Partner-linked variability

Zentalis Pharmaceuticals, Inc. can earn one-time commercial milestone payments if partnered assets reach launch, then collect royalties on net sales for the life of the license. This is a long-tail upside stream, but it is not a current cash engine: the company has not reported material royalty income, so near-term value depends on future partner approvals and sales.

• Launch milestones can trigger at approval
• Royalties scale with net product sales
• Current royalty revenue: not material

Zentalis Pharmaceuticals, Inc. can use research funding and cost sharing in strategic collaborations to offset development spend, reduce net cash burn, and keep pipeline work moving. In clinical-stage biotech, where one late-stage program can cost tens of millions of dollars, shared funding helps preserve capital for lead assets.

• Shared costs lower cash burn.
• Supports longer pipeline runway.
• Best fit for clinical-stage biotech.